Cargando…
Discovery of XL01126: A Potent, Fast, Cooperative, Selective, Orally Bioavailable, and Blood–Brain Barrier Penetrant PROTAC Degrader of Leucine-Rich Repeat Kinase 2
[Image: see text] Leucine-rich repeat kinase 2 (LRRK2) is one of the most promising targets for Parkinson’s disease. LRRK2-targeting strategies have primarily focused on type 1 kinase inhibitors, which, however, have limitations as the inhibited protein can interfere with natural mechanisms, which c...
Autores principales: | Liu, Xingui, Kalogeropulou, Alexia F., Domingos, Sofia, Makukhin, Nikolai, Nirujogi, Raja S., Singh, Francois, Shpiro, Natalia, Saalfrank, Anton, Sammler, Esther, Ganley, Ian G., Moreira, Rui, Alessi, Dario R., Ciulli, Alessio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2022
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9501899/ https://www.ncbi.nlm.nih.gov/pubmed/36007011 http://dx.doi.org/10.1021/jacs.2c05499 |
Ejemplares similares
-
Design and Characterization of SGK3-PROTAC1, an Isoform
Specific SGK3 Kinase PROTAC Degrader
por: Tovell, Hannah, et al.
Publicado: (2019) -
Impact of 100 LRRK2 variants linked to Parkinson's disease on kinase activity and microtubule binding
por: Kalogeropulou, Alexia F., et al.
Publicado: (2022) -
Development of a multiplexed targeted mass spectrometry assay for LRRK2-phosphorylated Rabs and Ser910/Ser935 biomarker sites
por: Nirujogi, Raja S., et al.
Publicado: (2021) -
Trivalent PROTACs enhance protein degradation via combined avidity and cooperativity
por: Imaide, Satomi, et al.
Publicado: (2021) -
A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo
por: Kofink, Christiane, et al.
Publicado: (2022)